Solna
Solna
Solna, Sweden71 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04663347 | |
| Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, Respiration Disorders, adult acute respiratory distress syndrome, influenza, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, severe acute respiratory syndrome, viral infectious disease, viral pneumonia | Recruiting | Phase 3 | 2026-10-02 | NCT05624450 | |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Digestive System Diseases, Intestinal Failure, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, disease, intestinal disorder, malabsorption syndrome, metabolic disease, short bowel syndrome, syndromic disease | Recruiting | Phase 3 | 2026-09-29 | NCT07197944 | |
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | mCRPC | Active, not recruiting | Phase 3 | 2026-09-29 | NCT03395197 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242484 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242471 | |
| A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 4 | 2026-09-25 | NCT04929210 | |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07190209 | |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | Skin and Connective Tissue Diseases, antisynthetase syndrome, connective tissue disorder, dermatomyositis, immune-mediated necrotizing myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder | Enrolling by invitation | Phase 3 | 2026-09-21 | NCT05979441 | |
| A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 1 | 2026-09-18 | NCT07220564 | |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Nutritional and Metabolic Diseases, amyloidosis, cardiomyopathy, cardiovascular disorder, heart disorder, metabolic disease, proteostasis deficiencies | Recruiting | Phase 3 | 2026-09-16 | NCT07052903 | |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-16 | NCT07037459 | |
| Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors | Haemophilia A Without Inhibitors; Haemophilia B Without Inhibitors | Active, not recruiting | Phase 3 | 2026-09-16 | NCT04082429 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 1 | 2026-09-09 | NCT07234942 | |
| A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-09-09 | NCT05968326 | |
| Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-09-09 | NCT05925530 | |
| Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors | Haemophilia A With Inhibitors; Haemophilia B With Inhibitors | Active, not recruiting | Phase 3 | 2026-09-09 | NCT04083781 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04680052 | |
| Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not stated | 2026-08-26 | NCT07690436 | |
| Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia | Bone Diseases, Developmental, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dwarfism, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, bone disorder, connective tissue disorder, cutaneous mucinosis, endocrine system disorder, hereditary disease, hypochondroplasia, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 4, musculoskeletal system disorder, osteochondrodysplasia | Enrolling by invitation | Phase 2 | 2026-08-26 | NCT07393373 | |
| REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Recruiting | Not stated | 2026-08-25 | NCT06557798 | |
| A Study of Pitolisant in Patients With Prader-Willi Syndrome | Abnormalities, Multiple, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disorders of Excessive Somnolence, Dyssomnias, Imprinting Disorders, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Overweight, Prader-Willi syndrome, Sleep Disorders, Intrinsic, chromosomal disorder, hereditary disease, intellectual disability, nervous system disorder, nutritional disorder, obesity disorder, overnutrition, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-08-25 | NCT06366464 | |
| Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry | Accidental Injuries, Aneurysm, Arterial Occlusive Diseases, Popliteal Artery Aneurysm, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, injury, peripheral arterial disease, peripheral vascular disease, vascular disorder | Active, not recruiting | Not stated | 2026-08-20 | NCT04907240 | |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Active, not recruiting | Phase 3 | 2026-08-17 | NCT04862663 |